Business Context and Reporting Period
This Form 8-K was filed by WellPoint, Inc. (now Elevance Health, Inc.) on April 13, 2009, reporting events occurring on April 9, 2009. The filing details the entry into a Material Definitive Agreement with Express Scripts, Inc. regarding the sale of WellPoint's pharmacy benefits management (PBM) business.
Key Financial Metrics and Transaction Details
- Total Transaction Value: $4.675 billion.
- Cash Consideration: $3.275 billion (subject to customary working capital and indebtedness adjustments).
- Stock Consideration: $1.400 billion in Express Scripts common stock.
- Assets Sold: All interests in NextRx, LLC, NextRx Services, Inc., and NextRx, Inc. (collectively the "Sold Entities").
- Termination Fee: $50 million payable by Express Scripts to WellPoint under specified circumstances related to U.S. antitrust approval.
Material Changes and Future Agreements
The transaction represents a significant divestiture of WellPoint's PBM operations. Upon closing, the parties will enter into three key agreements:
- A 10-year pharmacy benefits management contract where Express Scripts will provide services to WellPoint.
- A transition services agreement for WellPoint to provide temporary IT and related services to Express Scripts.
- A registration rights agreement regarding the Express Scripts stock received by WellPoint.
Conditions, Risks, and Contingencies
Consummation of the sale is subject to several material conditions, including:
- Receipt of U.S. antitrust and other required regulatory approvals without burdensome terms.
- Absence of laws or orders prohibiting the sale.
- Verification that the 2008 audited financial statements of the Sold Entities do not show a material deterioration in financial condition compared to unaudited statements previously delivered.
- Completion of specified system build-outs and modifications by December 31, 2009.
The filing notes that the agreement is not subject to any financing condition, as Express Scripts has already obtained debt financing commitments.
Investor Verification Checklist
- Verify the status of U.S. antitrust and regulatory approvals required for the transaction.
- Confirm the final working capital and indebtedness adjustments to the $3.275 billion cash component.
- Review the 2008 audited combined financial statements of the Sold Entities to ensure no material deterioration in financial condition.
- Monitor the progress of system build-outs and modifications required for closing.
- Assess the terms of the new 10-year PBM contract to understand future operational dependencies.